Published in EMBO J on February 01, 2001
Mutations in a gene encoding a novel SH3/TPR domain protein cause autosomal recessive Charcot-Marie-Tooth type 4C neuropathy. Am J Hum Genet (2003) 1.72
Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J (2006) 1.55
A genome-wide RNA interference screen identifies two novel components of the metazoan secretory pathway. EMBO J (2009) 1.31
Ultrastructural cartilage abnormalities in MIA/CD-RAP-deficient mice. Mol Cell Biol (2002) 1.06
Modulation of cartilage differentiation by melanoma inhibiting activity/cartilage-derived retinoic acid-sensitive protein (MIA/CD-RAP). Exp Mol Med (2010) 0.94
Reduced cholesterol and triglycerides in mice with a mutation in Mia2, a liver protein that localizes to ER exit sites. J Lipid Res (2011) 0.92
Mechanisms for exporting large-sized cargoes from the endoplasmic reticulum. Cell Mol Life Sci (2015) 0.89
Solution structure and dynamics of melanoma inhibitory activity protein. J Biomol NMR (2002) 0.84
Misexpression of MIA disrupts lung morphogenesis and causes neonatal death. Dev Biol (2008) 0.84
Targeting melanoma metastasis and immunosuppression with a new mode of melanoma inhibitory activity (MIA) protein inhibition. PLoS One (2012) 0.83
Backbone dynamics of the human MIA protein studied by (15)N NMR relaxation: implications for extended interactions of SH3 domains. Protein Sci (2003) 0.78
Small Molecules Antagonise the MIA-Fibronectin Interaction in Malignant Melanoma. Sci Rep (2016) 0.75
MOLMOL: a program for display and analysis of macromolecular structures. J Mol Graph (1996) 39.73
Protein structure comparison by alignment of distance matrices. J Mol Biol (1993) 34.74
SMART: a web-based tool for the study of genetically mobile domains. Nucleic Acids Res (2000) 17.77
Backbone dynamics of a free and phosphopeptide-complexed Src homology 2 domain studied by 15N NMR relaxation. Biochemistry (1994) 13.94
SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science (1991) 12.93
Enhanced genome annotation using structural profiles in the program 3D-PSSM. J Mol Biol (2000) 10.87
Relationship between nuclear magnetic resonance chemical shift and protein secondary structure. J Mol Biol (1991) 8.38
A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res (1987) 7.43
Improved spectral resolution in cosy 1H NMR spectra of proteins via double quantum filtering. Biochem Biophys Res Commun (1983) 7.26
Discovering high-affinity ligands for proteins: SAR by NMR. Science (1996) 7.10
Structural basis for the binding of proline-rich peptides to SH3 domains. Cell (1994) 6.34
Improved sensitivity of HSQC spectra of exchanging protons at short interscan delays using a new fast HSQC (FHSQC) detection scheme that avoids water saturation. J Magn Reson B (1995) 4.93
Two binding orientations for peptides to the Src SH3 domain: development of a general model for SH3-ligand interactions. Science (1994) 4.57
Experiment and theory highlight role of native state topology in SH3 folding. Nat Struct Biol (1999) 3.50
High-resolution crystal structures of tyrosine kinase SH3 domains complexed with proline-rich peptides. Nat Struct Biol (1994) 2.95
The folding transition state between SH3 domains is conformationally restricted and evolutionarily conserved. Nat Struct Biol (1999) 2.93
High-level expression of recombinant genes in Escherichia coli is dependent on the availability of the dnaY gene product. Gene (1989) 2.63
Solution structure of the SH3 domain of Src and identification of its ligand-binding site. Science (1992) 2.56
Biological and regulatory properties of Vav-3, a new member of the Vav family of oncoproteins. Mol Cell Biol (1999) 2.19
An optimized 3D NOESY-HSQC. J Magn Reson B (1996) 2.17
Practical introduction to theory and implementation of multinuclear, multidimensional nuclear magnetic resonance experiments. Methods Enzymol (1994) 1.88
Crystal structure of a heparin- and integrin-binding segment of human fibronectin. EMBO J (1999) 1.84
A novel peptide-SH3 interaction. EMBO J (1999) 1.61
Structural requirements for biological activity of the ninth and tenth FIII domains of human fibronectin. J Biol Chem (1997) 1.51
Localization and chemical synthesis of fibronectin peptides with melanoma adhesion and heparin binding activities. Biochemistry (1988) 1.49
S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol (1999) 1.49
Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res (1997) 1.42
Fibronectin structure and assembly. Curr Opin Cell Biol (1994) 1.40
Localization of the major heparin-binding site in fibronectin. J Biol Chem (1991) 1.35
Integrin alpha 4 beta 1-mediated melanoma cell adhesion and migration on vascular cell adhesion molecule-1 (VCAM-1) and the alternatively spliced IIICS region of fibronectin. J Biol Chem (1994) 1.34
Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res (1994) 1.32
Identification of a novel recognition sequence for the integrin alpha 4 beta 1 in the COOH-terminal heparin-binding domain of fibronectin. EMBO J (1991) 1.31
SH3 domains and drug design: ligands, structure, and biological function. Biopolymers (1997) 1.26
Use of a water flip-back pulse in the homonuclear NOESY experiment. J Biomol NMR (1995) 1.24
Interaction of heparin with fibronectin and isolated fibronectin domains. Biochem J (1990) 1.20
Chi 1 angle information from a simple two-dimensional NMR experiment that identifies trans 3JNC gamma couplings in isotopically enriched proteins. J Biomol NMR (1997) 1.15
Cloning of a retinoic acid-sensitive mRNA expressed in cartilage and during chondrogenesis. J Biol Chem (1996) 1.10
NMR analysis of interacting soluble forms of the cell-cell recognition molecules CD2 and CD48. Biochemistry (1996) 1.07
Determination of the disulphide bonding pattern in proteins by local and global analysis of nuclear magnetic resonance data. Application to flavoridin. J Mol Biol (1993) 1.06
Identification of melanoma inhibitory activity and other differentially expressed messenger RNAs in human melanoma cell lines with different metastatic capacity by messenger RNA differential display. Cancer Res (1995) 1.02
Evidence that binding to the carboxyl-terminal heparin-binding domain (Hep II) dominates the interaction between plasma fibronectin and heparin. Biochemistry (1988) 0.94
MIA (melanoma inhibitory activity): a potential serum marker for rheumatoid arthritis. Rheumatology (Oxford) (1999) 0.94
Structure of interleukin 16 resembles a PDZ domain with an occluded peptide binding site. Nat Struct Biol (1998) 0.92
Autocrine tumor cell growth-inhibiting activities from human malignant melanoma. Cancer Res (1989) 0.91
Structural features of fibronectin synthetic peptide FN-C/H II, responsible for cell adhesion, neurite extension, and heparan sulfate binding. J Biol Chem (1993) 0.90
The novel recognition site in the C-terminal heparin-binding domain of fibronectin by integrin alpha 4 beta 1 receptor on HL-60 cells. Exp Cell Res (1996) 0.86
[MIA ("melanoma inhibitory activity"). Biological functions and clinical relevance in malignant melanoma]. Hautarzt (1998) 0.85
Sequence-specific 1H, 13C, and 15N assignment of the human melanoma inhibitory activity (MIA) protein. J Biomol NMR (2000) 0.85
Identification of a novel binding site to the integrin alphaIIbbeta3 located in the C-terminal heparin-binding domain of human plasma fibronectin. J Biol Chem (1996) 0.83
Characterization of selected strongly and weakly invasive sublines of a primary human melanoma cell line and isolation of subtractive cDNA clones. Int J Cancer (1995) 0.82
An Improved Homonuclear TOCSY Experiment with Minimal Water Saturation J Magn Reson B (1996) 0.81
Conformation of thymosin beta 9 in water/fluoroalcohol solution determined by NMR spectroscopy. Biopolymers (1997) 0.80
Melanoma-inhibitory activity protein concentrations in blood of melanoma patients treated with immunotherapy. Oncol Res (1999) 0.79
Separation of anisotropy and exchange broadening using (15)N CSA-(15)N-(1)H dipole-dipole relaxation cross-correlation experiments. J Magn Reson (2000) 0.78
Sequence-specific 1H, 15N, and 13C assignment of the N-terminal domain of the human oncoprotein MDM2 that binds to p53. J Biomol NMR (2000) 0.77
MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature (1993) 5.60
Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry (1994) 3.58
A new family of human histone deacetylases related to Saccharomyces cerevisiae HDA1p. J Biol Chem (1999) 2.82
Identification of a penta- and hexapeptide of islet amyloid polypeptide (IAPP) with amyloidogenic and cytotoxic properties. J Mol Biol (2000) 2.34
FHL2, a novel tissue-specific coactivator of the androgen receptor. EMBO J (2000) 2.25
Crystal structure of a thermostable type B DNA polymerase from Thermococcus gorgonarius. Proc Natl Acad Sci U S A (1999) 2.19
Regulatory roles of AP-2 transcription factors in vertebrate development, apoptosis and cell-cycle control. Gene (2000) 2.07
Structure in solution of the major cold-shock protein from Bacillus subtilis. Nature (1993) 2.04
The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity. EMBO J (1991) 1.99
Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor Snail. J Biol Chem (2001) 1.98
Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J Biol Chem (2001) 1.97
Cloning and characterization of a second AP-2 transcription factor: AP-2 beta. Development (1995) 1.95
Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. FASEB J (2001) 1.91
Conformational transitions of islet amyloid polypeptide (IAPP) in amyloid formation in vitro. J Mol Biol (1999) 1.89
Involvement of ezrin/moesin in de novo actin assembly on phagosomal membranes. EMBO J (2000) 1.85
Transcriptional activation by Myc is under negative control by the transcription factor AP-2. EMBO J (1995) 1.82
Characterization of Cd, Zn-thionein (metallothionein) isolated from rat and chicken liver. Eur J Biochem (1973) 1.79
Enhanced apoptotic cell death of renal epithelial cells in mice lacking transcription factor AP-2beta. Genes Dev (1997) 1.76
Expression, function and clinical relevance of MIA (melanoma inhibitory activity). Histol Histopathol (2002) 1.73
EB/RP gene family encodes tubulin binding proteins. Int J Cancer (1999) 1.63
Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Clin Cancer Res (2001) 1.62
Conformation of thymosin beta 4 in water determined by NMR spectroscopy. Eur J Biochem (1993) 1.62
Reaction mechanism of Escherichia coli dihydrodipicolinate synthase investigated by X-ray crystallography and NMR spectroscopy. Biochemistry (1997) 1.62
Pheromone cross-inhibition between Staphylococcus aureus and Staphylococcus epidermidis. Infect Immun (2001) 1.59
Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome. J Pathol (2008) 1.56
Expression of Dickkopf genes is strongly reduced in malignant melanoma. Oncogene (2006) 1.53
Structural and functional analysis of the NF-kappa B p65 C terminus. An acidic and modular transactivation domain with the potential to adopt an alpha-helical conformation. J Biol Chem (1994) 1.50
Mutational analysis of the putative nucleic acid-binding surface of the cold-shock domain, CspB, revealed an essential role of aromatic and basic residues in binding of single-stranded DNA containing the Y-box motif. Mol Microbiol (1995) 1.44
Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res (1997) 1.42
Role of miRNAs in the progression of malignant melanoma. Br J Cancer (2009) 1.41
Repetitive training of compensatory steps: a therapeutic approach for postural instability in Parkinson's disease. J Neurol Neurosurg Psychiatry (2004) 1.39
Expression of Hugl-1 is strongly reduced in malignant melanoma. Oncogene (2006) 1.38
Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation. Leukemia (2012) 1.35
X-ray structure of active site-inhibited clotting factor Xa. Implications for drug design and substrate recognition. J Biol Chem (1996) 1.33
Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res (1994) 1.32
Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry (2001) 1.30
[Dissociation equilibrium of glutathione. A Fourier transform-13C-NMR spectroscopic study of pH-dependence and of charge densities]. Eur J Biochem (1972) 1.30
Structure of the IGF-binding domain of the insulin-like growth factor-binding protein-5 (IGFBP-5): implications for IGF and IGF-I receptor interactions. EMBO J (1998) 1.29
Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunology (2000) 1.29
Association between serum ferritin and the insulin resistance syndrome in a representative population. Eur J Endocrinol (2006) 1.28
Comparative analysis of AP-2 alpha and AP-2 beta gene expression during murine embryogenesis. Dev Dyn (1997) 1.28
Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie (2003) 1.27
Solution structure of PCP, a prototype for the peptidyl carrier domains of modular peptide synthetases. Structure (2000) 1.26
Treatment of renal stones by extracorporeal shockwave lithotripsy: an update. Eur Urol (2001) 1.23
N-ras oncogene causes AP-2 transcriptional self-interference, which leads to transformation. Genes Dev (1994) 1.22
Transcriptional regulation of the AP-2alpha promoter by BTEB-1 and AP-2rep, a novel wt-1/egr-related zinc finger repressor. Mol Cell Biol (1999) 1.21
Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential. Structure (1997) 1.21
The repeating segments of the F-actin cross-linking gelation factor (ABP-120) have an immunoglobulin-like fold. Nat Struct Biol (1997) 1.18
The 1.8-A crystal structure of a matrix metalloproteinase 8-barbiturate inhibitor complex reveals a previously unobserved mechanism for collagenase substrate recognition. J Biol Chem (2001) 1.17
Cloning and characterization of a fourth human somatostatin receptor. Proc Natl Acad Sci U S A (1993) 1.17
Magnetic circular dichroism studies. XII. The determination of tryptophan in proteins. J Am Chem Soc (1971) 1.15
Loss of E-cadherin leads to upregulation of NFkappaB activity in malignant melanoma. Oncogene (2004) 1.14
Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis. Cancer Res (1999) 1.14
[13C-NMR chemical shifts of amino acids and peptides]. Z Naturforsch B (1971) 1.13
Increased serum levels of non-collagenous matrix proteins (cartilage oligomeric matrix protein and melanoma inhibitory activity) in marathon runners. Osteoarthritis Cartilage (2000) 1.12
Mouse CD-RAP/MIA gene: structure, chromosomal localization, and expression in cartilage and chondrosarcoma. Dev Dyn (1997) 1.11
Intramolecular autoproteolysis initiates the maturation of penicillin amidase from Escherichia coli. Biochim Biophys Acta (1999) 1.10
Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? J Urol (2001) 1.10
Coagulation factor IXa: the relaxed conformation of Tyr99 blocks substrate binding. Structure (1999) 1.09
Relaxation matrix refinement of the solution structure of squash trypsin inhibitor. J Mol Biol (1991) 1.09
The interaction of insulin-like growth factor-I with the N-terminal domain of IGFBP-5. EMBO J (2001) 1.08
Influence of the cytoplasmic domain of E-cadherin on endogenous N-cadherin expression in malignant melanoma. Oncogene (2006) 1.08
Lysine 156 promotes the anomalous proenzyme activity of tPA: X-ray crystal structure of single-chain human tPA. EMBO J (1997) 1.08
Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma. J Pathol (2008) 1.07
Contribution of advanced glycosylation to the amyloidogenicity of islet amyloid polypeptide. Eur J Biochem (1998) 1.06
Structure and dynamics of the human granulocyte colony-stimulating factor determined by NMR spectroscopy. Loop mobility in a four-helix-bundle protein. Biochemistry (1994) 1.06
Determination of the three-dimensional structure of the bifunctional alpha-amylase/trypsin inhibitor from ragi seeds by NMR spectroscopy. Biochemistry (1995) 1.05
The helix-loop-helix transcription factor SEF-2 regulates the activity of a novel initiator element in the promoter of the human somatostatin receptor II gene. EMBO J (1996) 1.05
Induction of AP-2alpha expression by adenoviral infection involves inactivation of the AP-2rep transcriptional corepressor CtBP1. J Biol Chem (2001) 1.04
Solution conformation of thymosin beta 4: a nuclear magnetic resonance and simulated annealing study. Biochemistry (1990) 1.04
The genomic structure of the human AP-2 transcription factor. Nucleic Acids Res (1994) 1.04
Structure of hisactophilin is similar to interleukin-1 beta and fibroblast growth factor. Nature (1992) 1.03
Neurocan is dispensable for brain development. Mol Cell Biol (2001) 1.02
Structure of human cyclin-dependent kinase inhibitor p19INK4d: comparison to known ankyrin-repeat-containing structures and implications for the dysfunction of tumor suppressor p16INK4a. Structure (1998) 1.02
Differential effects of deoxycholic acid and taurodeoxycholic acid on NF-kappa B signal transduction and IL-8 gene expression in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol (2004) 1.01
Clinical and epidemiological picture of B pertussis and B parapertussis infections after introduction of acellular pertussis vaccines. Arch Dis Child (2003) 1.01
Cloning and in situ localization of a brain-derived porin that constitutes a large-conductance anion channel in astrocytic plasma membranes. Proc Natl Acad Sci U S A (1994) 1.01
High thermostability and lack of cooperative DNA binding distinguish the p63 core domain from the homologous tumor suppressor p53. J Biol Chem (2001) 1.01
The management of complex renal stones. BJU Int (2000) 1.01
In vitro modulation of human melanoma cell invasion and proliferation by all-trans-retinoic acid. Melanoma Res (1998) 1.00
Regulation of mesenchymal stem cell and chondrocyte differentiation by MIA. Exp Cell Res (2005) 1.00